NASDAQ:STOK

Stoke Therapeutics Stock Forecast, Price & News

$40.17

+1.36 (+3.50 %)

(As of 10/23/2020 12:00 AM ET)

Add

Compare

Today's Range

$38.86

Now: $40.17▼

$40.99

50-Day Range

$28.00

MA: $34.95▼

$39.32

52-Week Range

$15.82

Now: $40.17▼

$41.00

Volume64,000 shs

Average Volume150,962 shs

Market Capitalization$1.34 billion

P/E RatioN/A

Dividend YieldN/A

Beta0.23

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops antisense oligonucleotide medicines to treat the underlying causes of severe genetic diseases. Its lead product candidate, STK-001, to treat Dravet syndrome, a severe and progressive genetic epilepsy. Stoke Therapeutics, Inc. has a partnership with Invitae Corporation to offer epilepsy panel testing. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was founded in 2014 and is headquartered in Bedford, Massachusetts.

Beat the Market (BTM) Rank^™

1.4 Analyst's Opinion

Consensus Rating
Stoke Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $39.29, Stoke Therapeutics has a forecasted downside of 2.2% from its current price of $40.17.
Amount of Analyst Coverage
Stoke Therapeutics has only been the subject of 4 research reports in the past 90 days.

2.8 Community Rank

Outperform Votes
Stoke Therapeutics has received 50 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Stoke Therapeutics has received 39 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Stoke Therapeutics has received 56.18% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Stoke Therapeutics and other stocks. Vote “Outperform” if you believe STOK will outperform the S&P 500 over the long term. Vote “Underperform” if you believe STOK will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Stoke Therapeutics does not currently pay a dividend.
Dividend Growth
Stoke Therapeutics does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Stoke Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,849,206.00 in company stock.
Percentage Held by Insiders
54.60% of the stock of Stoke Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Stoke Therapeutics are expected to decrease in the coming year, from ($1.60) to ($1.90) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Stoke Therapeutics is -22.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Stoke Therapeutics is -22.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Stoke Therapeutics has a P/B Ratio of 5.86. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.05 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:STOK

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.stoketherapeutics.com

Phone781-430-8200

Employees44

Debt

Debt-to-Equity RatioN/A

Current Ratio35.41

Quick Ratio35.41

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value$6.86 per share

Price / Book5.86

Profitability

EPS (Most Recent Fiscal Year)($1.80)

Net Income$-32,330,000.00

Net MarginsN/A

Return on Equity-19.53%

Return on Assets-19.03%

Miscellaneous

Outstanding Shares33,241,000

Market Cap$1.34 billion

Next Earnings Date11/10/2020 (Estimated)

OptionableNot Optionable

$40.17

+1.36 (+3.50 %)

(As of 10/23/2020 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive STOK News and Ratings via Email

Sign-up to receive the latest news and ratings for STOK and its competitors with MarketBeat's FREE daily newsletter.

Stoke Therapeutics (NASDAQ:STOK) Frequently Asked Questions

How has Stoke Therapeutics' stock price been impacted by Coronavirus?

Stoke Therapeutics' stock was trading at $19.73 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, STOK stock has increased by 103.6% and is now trading at $40.17.
View which stocks have been most impacted by COVID-19.

Do Wall Street analysts recommend investors buy shares of Stoke Therapeutics?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Stoke Therapeutics in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Stoke Therapeutics.

When is Stoke Therapeutics' next earnings date?

Stoke Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Stoke Therapeutics.

How were Stoke Therapeutics' earnings last quarter?

Stoke Therapeutics (NASDAQ:STOK) released its quarterly earnings results on Monday, August, 10th. The company reported ($0.39) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.35) by $0.04.
View Stoke Therapeutics' earnings history.

What price target have analysts set for STOK?

8 brokers have issued twelve-month target prices for Stoke Therapeutics' stock. Their forecasts range from $30.00 to $49.00. On average, they expect Stoke Therapeutics' stock price to reach $39.29 in the next twelve months. This suggests that the stock has a possible downside of 2.2%.
View analysts' price targets for Stoke Therapeutics.

Who are some of Stoke Therapeutics' key competitors?

Some companies that are related to Stoke Therapeutics include Emergent Biosolutions (EBS), BridgeBio Pharma (BBIO), Amicus Therapeutics (FOLD), Biohaven Pharmaceutical (BHVN), Arena Pharmaceuticals (ARNA), Allakos (ALLK), Turning Point Therapeutics (TPTX), Evotec (EVTCY), Hutchison China MediTech (HCM), ChemoCentryx (CCXI), Reata Pharmaceuticals (RETA), FibroGen (FGEN), Schrödinger (SDGR), Insmed (INSM) and Sage Therapeutics (SAGE).
View all competitors.

What other stocks do shareholders of Stoke Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Stoke Therapeutics investors own include Gossamer Bio (GOSS), Editas Medicine (EDIT), Alector (ALEC), LogicBio Therapeutics (LOGC), NVIDIA (NVDA), Precision BioSciences (DTIL), Kaleido Biosciences (KLDO), Homology Medicines (FIXX), Marvell Technology Group (MRVL) and InVitae (NVTA).

Who are Stoke Therapeutics' key executives?

Stoke Therapeutics' management team includes the following people:

Dr. Edward M. Kaye, CEO & Director (Age 70)
Dr. Adrian R. Krainer, Co-Founder & Director (Age 60)
Ms. Isabel Aznarez, Co-Founder, VP & Head of Biology
Mr. Stephen J. Tulipano CPA, MBA, Chief Financial Officer (Age 60)
Dr. Huw M. Nash Ph.D., COO & Chief Bus. Officer (Age 52)

When did Stoke Therapeutics IPO?

(STOK) raised $100 million in an IPO on Wednesday, June 19th 2019. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Cowen and Credit Suisse served as the underwriters for the IPO and Canaccord Genuity was co-manager.

What is Stoke Therapeutics' stock symbol?

Stoke Therapeutics trades on the NASDAQ under the ticker symbol "STOK."

How do I buy shares of Stoke Therapeutics?

Shares of STOK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Stoke Therapeutics' stock price today?

One share of STOK stock can currently be purchased for approximately $40.17.

How big of a company is Stoke Therapeutics?

Stoke Therapeutics has a market capitalization of $1.34 billion. The company earns $-32,330,000.00 in net income (profit) each year or ($1.80) on an earnings per share basis. Stoke Therapeutics employs 44 workers across the globe.

What is Stoke Therapeutics' official website?

The official website for Stoke Therapeutics is www.stoketherapeutics.com.

How can I contact Stoke Therapeutics?

Stoke Therapeutics' mailing address is 45 WIGGINS AVENUE, BEDFORD MA, 01730. The company can be reached via phone at 781-430-8200 or via email at [email protected]

This page was last updated on 10/26/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Get Started with MarketBeat

	Read Your Daily Newsletter
	Check Out My MarketBeat
	Watch Our Tutorial Videos
	Add a Stock to Your Watchlist
	Set Up an Instant Alert
	View a Company's Profile Page
	View Our Financial Calendars
	View Today's Analyst Ratings